Table 2.

Other representative inhibitors of DUBs.

DUB inhibitor	Target	Structure	Stage of development	IC50	Reference
SJB3-019A	USP1		Preclinical	78.1 nM	[119]
ML323	USP1		Preclinical	76 nM	[120]
ML364	USP2		Preclinical	1.1 μM	[121]
P5091	USP7		Preclinical	4.2 μM	[122, 123]
FT671	USP7		Preclinical	52 nM	[124]
GNE-6776	USP7		Preclinical	N.A.	[125]
DUBs-IN-1	USP8		Preclinical	0.24 μM	[126]
Spautin1	USP13 and USP10		Preclinical	0.6–0.7 μM	[127, 128]
Mitoxantrone	USP11		Preclinical	8.5 μM	[129]
IU1	USP14		Preclinical	4–5 μM	[130]
IU1-47	USP14		Preclinical	0.6 μM	[131]
IU1-248	USP14		Preclinical	0.83 μM	[132]
PR619	Broad range DUB inhibitor		Preclinical		[133, 134]
1,10-Phenanthroline	JAMM type Isopeptidase		Preclinical		[135]
VLX1570	USP14 and UCHL5		Clinical trial phase (now suspended)	10 μM	[136]
GSK2643943A	USP20/Ub-Rho		Preclinical	160 nM	[43]